Impairment of insulin action and metabolic dysregulation have traditionally been associated
with schizophrenia, although the molecular basis of such association remains still elusive …

Background Schizophrenia is a disabling disorder that profoundly affects functioning and
quality of life. While available antipsychotics have improved outcomes for patients with …

There are no approved medicines for fragile X syndrome (FXS), a monogenic,
neurodevelopmental disorder. Electroencephalogram (EEG) studies show alterations in …

Clozapine is listed as one of the most effective antipsychotics and has been approved for
treating treatment-resistant schizophrenia (TRS); however, several type A and B adverse …

Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide
and is conceptualized as a disorder of synaptic plasticity and brain connectivity …

Introduction Treatment resistant schizophrenia (TRS), the lack of response to at least two
antipsychotics administered at adequate dose and duration, epitomizes in psychiatry one of …

Schizophrenia is a severe mental illness characterized by alterations in processes that
regulate both synaptic plasticity and functional connectivity between brain regions …

Clozapine is the only antipsychotic approved for treating treatment-resistant schizophrenia
(TRS), characterized by persistent positive symptoms despite adequate antipsychotic …

The advent of dopamine (D2) receptor-blocking medications over 70 years ago, ushered in
a new era of biological treatment for schizophrenia. However, we argue that little …

Behavioural supersensitivity may be a result of increased glutamate sensitivity of D2-MSN
and reduced sensitivity to dopamine. We propose that clozapine may address behavioural …